Suggestions(1)
Exact(3)
The 5-year survival rate was 62.5% for patients with p53-negative tumours and 43.3% for those with positive malignancies.
However a novel generation of c-kit inhibitors which are currently under investigation might be efficient on a larger spectrum of c-kit positive malignancies [ 28].
This study provides preliminary data to describe the association between several patients' baseline characteristics and infections during therapy with R. Rituximab (R) is a chimeric human-murine monoclonal antibody used to treat CD20 positive malignancies and autoimmune diseases.
Similar(57)
These findings demonstrate that 64Cu-DOTA-trastuzumab PET/CT might be applicable not only for breast cancer, but for other kinds of HER2-positive malignancies as well.
This development opens the possibility of targeted therapy for ALK-positive malignancies.
Moreover, EGFR-positive malignancies from bilio-digestive origin are associated with unfavourable outcome [ 11].
Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies.
Thus, further exploration of this novel fusion protein is warranted as a possible therapeutic for patients with MUC16-positive malignancies.
Since HSP70 promotes natural killer (NK -cell activity agaiNK -cellrs, we exactivityagainstg of some CD99-positumorsalignancies – B and T ALLs, ETs – by cytotoxic NK92 cell line.
Although the direct targeting of ALK may be preferential for treatment of ALK-positive malignancies, other approaches may provide a beneficial complement.
Moreover, age at menarche and time between menarche and first full-term childbirth may be associated with the etiology of both HR-negative and HR-positive malignancies, although associations were only borderline significant for HR-negative tumors.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com